Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
出版年份 2012 全文链接
标题
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
作者
关键词
-
出版物
MEDICAL ONCOLOGY
Volume 29, Issue 5, Pages 3291-3297
出版商
Springer Nature
发表日期
2012-03-29
DOI
10.1007/s12032-012-0227-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma
- (2011) E. Herrmann et al. WORLD JOURNAL OF UROLOGY
- Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
- (2010) Manuela Schmidinger et al. CANCER TREATMENT REVIEWS
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- (2009) Premal H. Patel et al. Clinical Genitourinary Cancer
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
- (2009) Giuseppe Di Lorenzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
- (2009) M.P. Sablin et al. JOURNAL OF UROLOGY
- Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
- (2008) Arkadiusz Z. Dudek et al. CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
- (2008) Christian Eichelberg et al. EUROPEAN UROLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started